Terms: = Cervical cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Prognosis
5 results:
1. HDACs alters negatively to the tumor immune microenvironment in gynecologic cancers.
Yan M; Cao H; Tao K; Xiao B; Chu Y; Ma D; Huang X; Han Y; Ji T
Gene; 2023 Nov; 885():147704. PubMed ID: 37572797
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterization of cervical cancer based on human papillomavirus status.
Zhang L; Jiang Y; Lu X; Zhao H; Chen C; Wang Y; Hu W; Zhu Y; Yan H; Yan F
Gynecol Oncol; 2019 Mar; 152(3):629-637. PubMed ID: 30581036
[TBL] [Abstract] [Full Text] [Related]
3. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
[TBL] [Abstract] [Full Text] [Related]
4. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
[TBL] [Abstract] [Full Text] [Related]
5. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix.
Perez CA; Grigsby PW; Chao KS; Mutch DG; Lockett MA
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):307-17. PubMed ID: 9607346
[TBL] [Abstract] [Full Text] [Related]
